

Embarc Benefit ProtectionSM



Breakthrough, potentially life-changing gene therapies are emerging at a promising rate. The FDA anticipates that by 2025 it will be approving from 10 to 20 gene and cell therapies each year.¹

Unfortunately, these gene therapies are expensive; a single treatment can cost millions of dollars. Annual gene therapy expenses are expected to reach more than \$8.6 billion by 2024.¹ These high costs threaten access to these potentially life changing therapies if plans cannot afford to cover them.

Did you know?

10%

of Americans have a rare condition related to a genetic defect.²

Embarc Benefit ProtectionSM —developed by eviCore healthcare (eviCore)—provides a solution to this potential problem.

Embarc Benefit ProtectionSM offers financial protection for the first two high-cost gene therapies to reach the marketplace: Luxturna[®], which is used to treat a rare form of inherited retinal dystrophy at a cost of \$850k per treatment (two eyes) and Zolgensma[®], a one-time treatment for spinal muscular atrophy at a cost of \$2.1M per treatment.

SHIELDING PAYERS AND PATIENTS

Embarc Benefit ProtectionSM is a network solution that combines the health services, medical management, and specialty pharmacy expertise of eviCore, Accredo, and Express Scripts to protect health plans and members from the high cost of breakthrough gene therapy drugs, and thereby help ensure access for those who need them.

Our combined organizations bring outstanding experience to support this solution for high-cost therapies:

- ✓ **Creating** financial protection
- ✓ **Leveraging** best-in-class specialty pharmacy
- ✓ **Connecting** members with best-in-class providers
- ✓ **Offering** predictable pricing

¹ EvaluatePharma, Evaluate Ltd, London UK. www.evaluate.com. Accessed 8/14/2019.

² EvaluatePharma Orphan Drug Report 2018. 5th Edition, May 2018. www.evaluategroup.com/OrphanDrug2018.



Embarc Benefit ProtectionSM

Did you know?

>18

gene therapies will seek FDA approval in the next two to three years.³

NEXT STEPS

Luxturna[®] and Zolgensma[®] are included in this first-generation solution, as they are the only two gene therapy products currently in the U.S. marketplace. A 5-year pipeline of drugs and drug categories is now under assessment. eviCore will determine whether additional therapies will be added to Embarc Benefit ProtectionSM as they come to market.

.....



99¢
PMPM

SOLUTION PRICING

The solution is designed to make these two revolutionary gene therapy drugs accessible to members at no out-of-pocket charges or additional expense to the plan, when covered under the plan and medically necessary.⁵ Clients will pay a per member, per month (PMPM) charge of \$0.99. eviCore arranges for the provision of the most expensive component of the overall gene therapy: the drugs themselves. The Embarc Benefit ProtectionSM solution does not apply to costs, including facility and professional charges, associated with the administration of the therapies to patients.

.....

Did you know?

Future gene therapies are projected to have **multi-million** dollar prices.⁴

We can't afford to fail.

For more information:
sales@evicore.com

³ Richter S, Yeh R, Weinreb, R, et al. The Genome Revolution. The Goldman Sachs Group, Inc. April 10, 2018.

⁴ EvaluatePharma, Evaluate Ltd, London UK, www.evaluate.com Accessed 8/14/2019.

⁵ Members with an HSA must have met the applicable minimum deductible required for a high deductible health plan.

